Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2019 Filed Mar 11, 2019 21:15 UTC |
Scanlan JacquelineSVP, Global Human Resources
|
SaleCommon Stock | 116 | $83.57 | $9,694.12 |
DisclosureSEC source: 0001127602-19-010840 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,446 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 21:10 UTC |
Basil Michelle LEVP and General Counsel
|
SaleCommon Stock | 391 | $83.57 | $32,675.87 |
DisclosureSEC source: 0001127602-19-010837 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,879 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:20 UTC |
GELBMAN RONALD GDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,196 | $0.00 Strike: $36.37 | $0.00 |
DisclosureSEC source: 0001127602-19-006806 · form4.xml · derivative · entry 3 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,196 shares Expires 2019-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:20 UTC |
GELBMAN RONALD GDirector
|
SaleCommon Stock | 8,196 | $86.52 | $709,117.92 |
DisclosureSEC source: 0001127602-19-006806 · form4.xml · nonDerivative · entry 2 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,062 F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:20 UTC |
GELBMAN RONALD GDirector
|
Exercise / conversionCommon Stock | 8,196 | $36.37 | $298,088.52 |
DisclosureSEC source: 0001127602-19-006806 · form4.xml · nonDerivative · entry 1 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| December 24, 2018 Filed May 13, 2019 21:14 UTC |
KROLL MARK WDirector
|
GiftCommon Stock | 1,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-018356 · form5.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,606 F1 · kind: Shares transferred as a bona fide gift without any consideration. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:04 UTC |
MEELIA RICHARD JDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,196 | $0.00 Strike: $36.37 | $0.00 |
DisclosureSEC source: 0001127602-18-036615 · form4.xml · derivative · entry 3 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,196 shares Expires 2019-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:04 UTC |
MEELIA RICHARD JDirector
|
SaleCommon Stock | 8,196 | $102.86 | $843,040.56 |
DisclosureSEC source: 0001127602-18-036615 · form4.xml · nonDerivative · entry 2 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,607 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.56 to $103.26, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:04 UTC |
MEELIA RICHARD JDirector
|
Exercise / conversionCommon Stock | 8,196 | $36.37 | $298,088.52 |
DisclosureSEC source: 0001127602-18-036615 · form4.xml · nonDerivative · entry 1 MEELIA RICHARD J · CIK 0001223633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 21:56 UTC |
GELBMAN RONALD GDirector
|
SaleCommon Stock | 4,329 | $103.02 | $445,973.58 |
DisclosureSEC source: 0001127602-18-036606 · form4.xml · nonDerivative · entry 1 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,062 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.96 to $103.10, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 22:38 UTC |
Scanlan JacquelineSVP, Global Human Resources
|
SaleCommon Stock | 1,027 | $104.22 | $107,033.94 |
DisclosureSEC source: 0001127602-18-036310 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,562 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported and 38 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2018. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 23:07 UTC |
Goldstein DanVP, Corporate Controller
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,457 | $0.00 Strike: $34.21 | $0.00 |
DisclosureSEC source: 0001127602-18-036101 · form4.xml · derivative · entry 3 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,913 Underlying: Common Stock · 1,457 shares Expires 2023-10-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 23:07 UTC |
Goldstein DanVP, Corporate Controller
|
SaleCommon Stock | 1,693 | $102.91 | $174,226.63 |
DisclosureSEC source: 0001127602-18-036101 · form4.xml · nonDerivative · entry 2 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,218 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 23:07 UTC |
Goldstein DanVP, Corporate Controller
|
Exercise / conversionCommon Stock | 1,457 | $34.21 | $49,843.97 |
DisclosureSEC source: 0001127602-18-036101 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 21:25 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 11,232 | $0.00 Strike: $34.21 | $0.00 |
DisclosureSEC source: 0001127602-18-032653 · form4.xml · derivative · entry 3 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,463 Underlying: Common Stock · 11,232 shares Expires 2023-10-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 21:25 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
SaleCommon Stock | 13,056 | $114.33 | $1,492,692.48 |
DisclosureSEC source: 0001127602-18-032653 · form4.xml · nonDerivative · entry 2 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,001 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 21:25 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 11,232 | $34.21 | $384,246.72 |
DisclosureSEC source: 0001127602-18-032653 · form4.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 21:10 UTC |
GRANADILLO PEDRO PDirector
|
SaleCommon Stock | 12,322 | $114.50 | $1,410,869.00 |
DisclosureSEC source: 0001127602-18-032638 · form4.xml · nonDerivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,335 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.50 to $114.60, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:06 UTC |
KROLL MARK WDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,196 | $0.00 Strike: $36.37 | $0.00 |
DisclosureSEC source: 0001127602-18-032628 · form4.xml · derivative · entry 5 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,196 shares Expires 2019-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:06 UTC |
KROLL MARK WDirector
|
SaleCommon Stock | 10,707 | $114.00 | $1,220,598.00 |
DisclosureSEC source: 0001127602-18-032628 · form4.xml · nonDerivative · entry 4 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,748 F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:06 UTC |
KROLL MARK WDirector
|
Exercise / conversionCommon Stock | 8,196 | $36.37 | $298,088.52 |
DisclosureSEC source: 0001127602-18-032628 · form4.xml · nonDerivative · entry 3 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 26, 2018 Filed Oct 30, 2018 21:11 UTC |
Goldstein DanVP, Corporate Controller
|
SaleCommon Stock | 102 | $101.69 | $10,372.38 |
DisclosureSEC source: 0001127602-18-031285 · form4.xml · nonDerivative · entry 1 Goldstein Dan · CIK 0001722327 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,454 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 26, 2018 Filed Oct 30, 2018 21:18 UTC |
Burke William P. Mr.EVP, Chief Financial Officer
|
SaleCommon Stock | 779 | $101.69 | $79,216.51 |
DisclosureSEC source: 0001127602-18-031291 · form4.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,825 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC |
GRANADILLO PEDRO PDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 10,353 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · derivative · entry 11 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,353 shares Expires 2021-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F8 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC |
GRANADILLO PEDRO PDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 6,573 | $0.00 Strike: $45.45 | $0.00 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · derivative · entry 10 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,573 shares Expires 2020-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F8 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC |
GRANADILLO PEDRO PDirector
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,196 | $0.00 Strike: $36.37 | $0.00 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · derivative · entry 9 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,196 shares Expires 2019-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F8 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC |
GRANADILLO PEDRO PDirector
|
SaleCommon Stock | 631 | $114.16 | $72,034.96 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 8 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,657 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114 to $114.44, inclusive. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC |
GRANADILLO PEDRO PDirector
|
SaleCommon Stock | 11,812 | $113.16 | $1,336,645.92 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 7 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,288 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.51 to $113.35, inclusive. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC |
GRANADILLO PEDRO PDirector
|
SaleCommon Stock | 13,183 | $111.33 | $1,467,663.39 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 6 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,100 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.92 to 111.88, inclusive. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC |
GRANADILLO PEDRO PDirector
|
SaleCommon Stock | 3,696 | $110.11 | $406,966.56 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 5 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,283 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.79 to $110.55, inclusive. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC |
GRANADILLO PEDRO PDirector
|
SaleCommon Stock | 1,502 | $108.92 | $163,597.84 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 4 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,979 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.61 to $109.33, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC |
GRANADILLO PEDRO PDirector
|
Exercise / conversionCommon Stock | 10,353 | $35.50 | $367,531.50 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 3 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC |
GRANADILLO PEDRO PDirector
|
Exercise / conversionCommon Stock | 6,573 | $45.45 | $298,742.85 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 2 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 21:00 UTC |
GRANADILLO PEDRO PDirector
|
Exercise / conversionCommon Stock | 8,196 | $36.37 | $298,088.52 |
DisclosureSEC source: 0001127602-18-028076 · form4.xml · nonDerivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:13 UTC |
Scanlan JacquelineSVP, Global Human Resources
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,889 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001127602-18-027485 · form4.xml · derivative · entry 7 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,669 Underlying: Common Stock · 2,889 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:13 UTC |
Scanlan JacquelineSVP, Global Human Resources
|
Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,299 | $0.00 Strike: $38.43 | $0.00 |
DisclosureSEC source: 0001127602-18-027485 · form4.xml · derivative · entry 6 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,898 Underlying: Common Stock · 1,299 shares Expires 2024-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:13 UTC |
Scanlan JacquelineSVP, Global Human Resources
|
SaleCommon Stock | 702 | $112.19 | $78,757.38 |
DisclosureSEC source: 0001127602-18-027485 · form4.xml · nonDerivative · entry 5 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,551 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:13 UTC |
Scanlan JacquelineSVP, Global Human Resources
|
SaleCommon Stock | 2,889 | $112.19 | $324,116.91 |
DisclosureSEC source: 0001127602-18-027485 · form4.xml · nonDerivative · entry 4 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,253 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:13 UTC |
Scanlan JacquelineSVP, Global Human Resources
|
Exercise / conversionCommon Stock | 2,889 | $41.64 | $120,297.96 |
DisclosureSEC source: 0001127602-18-027485 · form4.xml · nonDerivative · entry 3 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:13 UTC |
Scanlan JacquelineSVP, Global Human Resources
|
SaleCommon Stock | 1,299 | $112.19 | $145,734.81 |
DisclosureSEC source: 0001127602-18-027485 · form4.xml · nonDerivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,253 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 21:13 UTC |
Scanlan JacquelineSVP, Global Human Resources
|
Exercise / conversionCommon Stock | 1,299 | $38.43 | $49,920.57 |
DisclosureSEC source: 0001127602-18-027485 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:24 UTC |
Llorens JosepSVP, Global Manufacturing
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 4,714 | $0.00 Strike: $111.84 | $0.00 |
DisclosureSEC source: 0001127602-18-026964 · form4.xml · derivative · entry 2 Llorens Josep · CIK 0001750812 · SVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,714 Underlying: Common Stock · 4,714 shares Expires 2025-09-04 F3 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:24 UTC |
Llorens JosepSVP, Global Manufacturing
|
GrantCommon Stock | 1,341 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-026964 · form4.xml · nonDerivative · entry 1 Llorens Josep · CIK 0001750812 · SVP, Global Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,341 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| August 16, 2018 Filed Nov 9, 2018 21:06 UTC |
KROLL MARK WDirector
|
GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-032628 · form4.xml · nonDerivative · entry 2 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,259 F1 · kind: Shares transferred as a bona fide gift without any consideration. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| August 14, 2018 Filed Nov 9, 2018 21:06 UTC |
KROLL MARK WDirector
|
GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-032628 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,459 F1 · kind: Shares transferred as a bona fide gift without any consideration. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 22:29 UTC |
ABERNATHY ROBERT EDirector
|
GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024065 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,605 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 22:20 UTC |
KROLL MARK WDirector
|
GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024061 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,459 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 22:25 UTC |
Zane Ellen MDirector
|
GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024063 · form4.xml · nonDerivative · entry 1 Zane Ellen M · CIK 0001369850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,997 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 22:16 UTC |
GRANADILLO PEDRO PDirector
|
GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024059 · form4.xml · nonDerivative · entry 1 GRANADILLO PEDRO P · CIK 0001217544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,359 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 22:09 UTC |
GELBMAN RONALD GDirector
|
GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024057 · form4.xml · nonDerivative · entry 1 GELBMAN RONALD G · CIK 0001210616 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,391 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.